title: Possible drug-drug interaction between adalimumab and duloxetine and/or pregabalin in a psoriasis patient.
authors.forename: Rishu
authors.initials: R
authors.lastname: Gupta
authors.forename: Jashin J
authors.initials: JJ
authors.lastname: Wu
authors.forename: Ethan
authors.initials: E
authors.lastname: Levin
authors.forename: John Y M
authors.initials: JY
authors.lastname: Koo
authors.forename: Wilson
authors.initials: W
authors.lastname: Liao
mesh_terms: D000068879:Adalimumab; D000700:Analgesics / Q000009:adverse effects* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003929:Diabetic Neuropathies / Q000150:complications / Q000188:drug therapy; D004347:Drug Interactions; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D000069583:Pregabalin; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy; D013876:Thiophenes / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000928:Antidepressive Agents; D001688:Biological Products; D013876:Thiophenes; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D003577:Cytochrome P-450 Enzyme System; D000068736:Duloxetine Hydrochloride; D000068879:Adalimumab